BR112015005443A2 - tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico - Google Patents

tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico

Info

Publication number
BR112015005443A2
BR112015005443A2 BR112015005443A BR112015005443A BR112015005443A2 BR 112015005443 A2 BR112015005443 A2 BR 112015005443A2 BR 112015005443 A BR112015005443 A BR 112015005443A BR 112015005443 A BR112015005443 A BR 112015005443A BR 112015005443 A2 BR112015005443 A2 BR 112015005443A2
Authority
BR
Brazil
Prior art keywords
drug
netrin
interfering
chemotherapeutic
combination treatment
Prior art date
Application number
BR112015005443A
Other languages
English (en)
Inventor
Paradisi Andréa
Nony Pascale
Mehlen Patrick
Original Assignee
Netris Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netris Pharma filed Critical Netris Pharma
Publication of BR112015005443A2 publication Critical patent/BR112015005443A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

1/1 resumo “tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico” composição farmacêutica compreendendo um fármaco quimioterapêutico e um fármaco interferente de netrina-1 ou um vetor capaz de expressar um fármaco interferente de netrina-1 in vivo, em um carreador ou veículo farmaceuticamente aceitável. o fármaco quimioterapêutico é selecionado dentre aqueles que são capazes de induzir a superexpressão de netrina-1 em células cancerosas. a combinação está associada com o efeito aditivo anti-câncer.
BR112015005443A 2012-09-12 2013-09-12 tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico BR112015005443A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261700158P 2012-09-12 2012-09-12
EP12306100.4A EP2708231A1 (en) 2012-09-12 2012-09-12 Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
PCT/EP2013/068937 WO2014041088A2 (en) 2012-09-12 2013-09-12 Combined treatment with netrin-1 interfering drug and chemotherapeutic drug

Publications (1)

Publication Number Publication Date
BR112015005443A2 true BR112015005443A2 (pt) 2017-12-05

Family

ID=46924380

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015005443A BR112015005443A2 (pt) 2012-09-12 2013-09-12 tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico

Country Status (15)

Country Link
US (1) US9895439B2 (pt)
EP (2) EP2708231A1 (pt)
JP (1) JP6467604B2 (pt)
KR (1) KR102424439B1 (pt)
CN (2) CN104853756A (pt)
AU (1) AU2013314320B2 (pt)
BR (1) BR112015005443A2 (pt)
CA (1) CA2884834C (pt)
ES (1) ES2702733T3 (pt)
HK (1) HK1208379A1 (pt)
IL (1) IL237702B (pt)
MX (1) MX2015003343A (pt)
SG (1) SG11201501877WA (pt)
WO (1) WO2014041088A2 (pt)
ZA (1) ZA201502269B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2893939A1 (en) * 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
CN105031611B (zh) * 2015-06-18 2018-02-09 中国医学科学院基础医学研究所 netrin‑1蛋白在制备用于肿瘤治疗的药物中的用途
TW201720459A (zh) 2015-11-02 2017-06-16 妮翠斯製藥公司 Ntn1中和劑與抑制後生控制之藥物之組合治療
CN105861505A (zh) * 2016-05-31 2016-08-17 东北师范大学 靶向沉默UNC5A的shRNA
WO2018102375A1 (en) * 2016-11-29 2018-06-07 Health Research, Inc. Methods and compositions for cancer therapy
KR102679324B1 (ko) 2017-01-05 2024-06-28 네트리 파르마 네트린-1 간섭 약물과 면역 관문 억제제 약물의 조합 치료
CN112812167B (zh) * 2021-01-06 2023-04-11 东北师范大学 一种促进细胞存活的Netrin-1模拟肽、Netrin-1截短多肽及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5792608A (en) 1991-12-12 1998-08-11 Gilead Sciences, Inc. Nuclease stable and binding competent oligomers and methods for their use
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
AU2001293870A1 (en) 2000-10-16 2002-04-29 Bayer Aktiengesellschaft Regulation of human netrin binding membrane receptor unc5h-1
US7312243B1 (en) * 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
WO2005074556A2 (en) 2004-01-30 2005-08-18 The General Hospital Corporation Netrin compositions and methods of use thereof
CA2565524A1 (en) * 2004-06-04 2005-12-15 Applied Research Systems Ars Holding N.V. Splice variant of unc5h2
CA2573720A1 (en) 2004-07-14 2006-02-23 University Of Utah Research Foundation Netrin-related compositions and uses
EP2322206A3 (fr) * 2004-11-22 2013-06-05 Centre National de la Recherche Scientifique Nétrine 1 mutée, ses fragments et leur utilisation comme médicaments
US20060153840A1 (en) * 2005-01-12 2006-07-13 Anne Eichmann Methods for preventing or treating a condition or a disease associated with angiogenesis
JP5602368B2 (ja) 2006-02-28 2014-10-08 サントル、ナショナール、ド、ラ、ルシェルシュ、シアンティフィク、（セーエヌエルエス） ネトリン−１活性を用いた抗癌化合物のスクリーニング
WO2009141440A1 (en) 2008-05-21 2009-11-26 Centre National De La Recherche Scientifique (Cnrs) Netrin-1 overexpression as a biological marker and a survival factor for aggressive neuroblastoma
AR074369A1 (es) * 2008-11-20 2011-01-12 Genentech Inc Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
EP2208738A1 (en) * 2009-01-09 2010-07-21 Centre National pour la Recherche Scientifique (CNRS) Method for the selection of endothelial cells death inducers via netrin-1 and its applications
EP2609430A1 (en) 2010-08-26 2013-07-03 F.Hoffmann-La Roche Ag Recombinant fc-fusion protein of the fifth fibronectin type iii domain of dcc

Also Published As

Publication number Publication date
US9895439B2 (en) 2018-02-20
WO2014041088A3 (en) 2014-07-03
EP2895173B1 (en) 2018-11-14
CA2884834C (en) 2020-11-17
CA2884834A1 (en) 2014-03-20
EP2708231A1 (en) 2014-03-19
WO2014041088A2 (en) 2014-03-20
ES2702733T3 (es) 2019-03-05
AU2013314320B2 (en) 2017-04-06
KR102424439B1 (ko) 2022-07-21
MX2015003343A (es) 2015-10-22
KR20150079599A (ko) 2015-07-08
AU2013314320A1 (en) 2015-04-02
EP2895173A2 (en) 2015-07-22
JP2015529675A (ja) 2015-10-08
AU2013314320A2 (en) 2015-04-09
ZA201502269B (en) 2019-05-29
IL237702B (en) 2018-11-29
CN104853756A (zh) 2015-08-19
SG11201501877WA (en) 2015-04-29
HK1208379A1 (en) 2016-03-04
CN110522913A (zh) 2019-12-03
JP6467604B2 (ja) 2019-02-13
US20150246116A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
BR112015005443A2 (pt) tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico
CL2016001629A1 (es) Compuestos tricíclicos como agentes anticancerígenos
PH12016501171A1 (en) Peptidomimetic compounds and antibody-drug conjugates thereof
BR112015016681A8 (pt) uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático
MX2016007851A (es) Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos.
CL2015000897A1 (es) Composición farmacéutica que contiene un portador de oxígeno basado en hemoglobina para el tratamiento de focalización de cáncer y prevención de recurrencia de cáncer.
NZ749218A (en) Androgen receptor modulator and uses thereof
UY36075A (es) Derivados de tubulisina
MX2013010376A (es) Formulaciones estables para inyeccion parenteral de farmacos de peptido.
CL2013000016A1 (es) Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer.
MX2017014641A (es) Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa).
MX359210B (es) Composición de combinación de pac-1 y tamoxifeno.
CL2015001202A1 (es) Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer.
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
BR112015027607A2 (pt) usos de um ecd de fgfr1 ou uma molécula de fusão de ecd de fgfr1
CL2013003324A1 (es) Composicion que comprende quimioterapia con paclitaxel y carboplatino y un oligonucleotido anti-clusterina; uso de la composición para el tratamiento de un paciente humano que padece cancer de pulmón.
CL2014001959A1 (es) Compuestos derivados de fenil-1h-imidazo[1,2-b]pirazol sustituidos; procedimiento de preparacion; composicion farmaceutica; y el uso en el tratamiento del cancer.
NZ705124A (en) Interferon-beta for use as monotherapy or in combination with other cancer therapies
BR112013033544A2 (pt) dosagem e administração de anticorpos anti-erbb3 em combinação com paclitaxel para tratamento de cânceres ginecológicos
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
AU2013208104A8 (en) Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
JO3630B1 (ar) توليفة أليسيرتيب وباكليتاكسيل لعلاج السرطان
CL2008001322A1 (es) Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer.
MX2010009697A (es) Tratamientos anticancerigenos mejorados.
MX2011006532A (es) Compuestos anticancerigenos.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B25A Requested transfer of rights approved

Owner name: NETRIS PHARMA (FR) ; UNIVERSITE CLAUDE BERNARD LYON 1 (FR)

Owner name: NETRIS PHARMA (FR) ; UNIVERSITE CLAUDE BERNARD LYO

B25A Requested transfer of rights approved

Owner name: NETRIS PHARMA (FR) ; UNIVERSITE CLAUDE BERNARD LYON 1 (FR) ; CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR)

Owner name: NETRIS PHARMA (FR) ; UNIVERSITE CLAUDE BERNARD LYO

B25A Requested transfer of rights approved

Owner name: NETRIS PHARMA (FR) ; UNIVERSITE CLAUDE BERNARD LYO

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]